BRPI0608819A8 - CRYSTALLINE FORMS OF AN IMIDAZOLE DERIVATIVE - Google Patents
CRYSTALLINE FORMS OF AN IMIDAZOLE DERIVATIVEInfo
- Publication number
- BRPI0608819A8 BRPI0608819A8 BRPI0608819A BRPI0608819A BRPI0608819A8 BR PI0608819 A8 BRPI0608819 A8 BR PI0608819A8 BR PI0608819 A BRPI0608819 A BR PI0608819A BR PI0608819 A BRPI0608819 A BR PI0608819A BR PI0608819 A8 BRPI0608819 A8 BR PI0608819A8
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- imidazole derivative
- imidazole
- ethyl
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
Abstract
FORMAS CRISTALINAS DE UM DERIVADO DE IMIDAZOL A invenção refere-se às Formas Polimorfas A e B da N-[({2-[4-(2-etil-4,6-dimetil-1H-imidazol[4,5-c]piridin-1-il) -fenil]etil}amino)carbonil]-4-metil-benzenossulfoflamida, essencialmente puras, e à processos para a preparação de composições que as contêm, e aos usos de tais formas cristalinas.CRYSTALLINE FORMS OF AN IMIDAZOLE DERIVATIVE The invention relates to Polymorph Forms A and B of N-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c] pyridin-1-yl)-phenyl]ethyl}amino)carbonyl]-4-methyl-benzenesulfoflamide, essentially pure, and to processes for preparing compositions containing the same, and to the uses of such crystalline forms.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66059205P | 2005-03-11 | 2005-03-11 | |
US60/660.592 | 2005-03-11 | ||
PCT/IB2006/000754 WO2006095268A1 (en) | 2005-03-11 | 2006-03-01 | Crystal forms of an imidazole derivative |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0608819A2 BRPI0608819A2 (en) | 2010-01-26 |
BRPI0608819A8 true BRPI0608819A8 (en) | 2017-10-10 |
BRPI0608819B1 BRPI0608819B1 (en) | 2019-11-12 |
BRPI0608819B8 BRPI0608819B8 (en) | 2021-05-25 |
Family
ID=36649530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0608819A BRPI0608819B8 (en) | 2005-03-11 | 2006-03-01 | crystal forms of an imidazole derivative |
Country Status (21)
Country | Link |
---|---|
US (1) | US7960407B2 (en) |
EP (1) | EP1861400B1 (en) |
JP (1) | JP5069415B2 (en) |
KR (1) | KR100911073B1 (en) |
CN (1) | CN101137656B (en) |
AR (1) | AR055567A1 (en) |
AT (1) | ATE469150T1 (en) |
AU (1) | AU2006221699A1 (en) |
BR (1) | BRPI0608819B8 (en) |
CA (1) | CA2600510C (en) |
DE (1) | DE602006014516D1 (en) |
ES (1) | ES2344310T3 (en) |
IL (1) | IL185145A0 (en) |
IN (1) | IN2014DN09939A (en) |
MX (1) | MX2007011110A (en) |
NL (1) | NL300944I2 (en) |
PL (1) | PL1861400T3 (en) |
RU (1) | RU2357968C1 (en) |
TW (1) | TW200643021A (en) |
WO (1) | WO2006095268A1 (en) |
ZA (1) | ZA200707568B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2346866B1 (en) | 2008-09-25 | 2013-11-27 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
EP2422779B1 (en) | 2009-04-22 | 2016-01-06 | RaQualia Pharma Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
ES2600355T3 (en) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Use of an EP4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis |
RU2451680C1 (en) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clatrate complex of cyclodextrine or arabinogalactane with 9-phenyl-symm-octahydroselenoxantene, its production method (versions), pharmaceutical composition and medication |
RU2464042C1 (en) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | β-CYCLODEXTRINE CLATHRATE COMPLEX WITH 5-HYDROXY-4-AMINOMETHYL-1 -CYCLOHEXYL(OR CYCLOHEPTYL)-3-ALKOXYCARBONYLINDOLE DERIVATIVE, METHOD FOR PREPARING IT (VERSIONS), PHARMACEUTICAL COMPOSITION AND DRUG |
KR102556734B1 (en) * | 2013-03-19 | 2023-07-18 | 에스크엣 인크. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
KR101697914B1 (en) * | 2014-03-06 | 2017-01-18 | 아라타나 세라퓨틱스, 인크. | Crystalline forms of grapiprant |
CN105939713A (en) * | 2014-03-06 | 2016-09-14 | 阿莱塔纳治疗学股份有限公司 | Compositions of grapiprant and methods for using same |
US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
CA3096546A1 (en) | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
WO2020014445A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
WO2020014465A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
US11512088B2 (en) | 2019-01-30 | 2022-11-29 | Avista Pharma Solutions, Inc. | Synthetic process and intermediates |
EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | Chemical compounds |
US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2001000224A (en) * | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
AU2003214525B2 (en) * | 2002-04-12 | 2008-09-25 | Pfizer Inc. | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases |
-
2006
- 2006-03-01 CA CA2600510A patent/CA2600510C/en active Active
- 2006-03-01 DE DE602006014516T patent/DE602006014516D1/de active Active
- 2006-03-01 RU RU2007133802/04A patent/RU2357968C1/en active
- 2006-03-01 WO PCT/IB2006/000754 patent/WO2006095268A1/en active Application Filing
- 2006-03-01 PL PL06710609T patent/PL1861400T3/en unknown
- 2006-03-01 KR KR1020077020701A patent/KR100911073B1/en active IP Right Grant
- 2006-03-01 ES ES06710609T patent/ES2344310T3/en active Active
- 2006-03-01 US US11/908,163 patent/US7960407B2/en active Active
- 2006-03-01 MX MX2007011110A patent/MX2007011110A/en active IP Right Grant
- 2006-03-01 EP EP06710609A patent/EP1861400B1/en active Active
- 2006-03-01 BR BRPI0608819A patent/BRPI0608819B8/en active IP Right Grant
- 2006-03-01 AT AT06710609T patent/ATE469150T1/en not_active IP Right Cessation
- 2006-03-01 IN IN9939DEN2014 patent/IN2014DN09939A/en unknown
- 2006-03-01 AU AU2006221699A patent/AU2006221699A1/en not_active Abandoned
- 2006-03-01 CN CN2006800079642A patent/CN101137656B/en active Active
- 2006-03-09 TW TW095108018A patent/TW200643021A/en unknown
- 2006-03-09 AR ARP060100886A patent/AR055567A1/en unknown
- 2006-03-10 JP JP2006065731A patent/JP5069415B2/en active Active
-
2007
- 2007-08-09 IL IL185145A patent/IL185145A0/en unknown
- 2007-09-03 ZA ZA200707568A patent/ZA200707568B/en unknown
-
2018
- 2018-07-05 NL NL300944C patent/NL300944I2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006221699A1 (en) | 2006-09-14 |
RU2357968C1 (en) | 2009-06-10 |
IL185145A0 (en) | 2007-12-03 |
JP5069415B2 (en) | 2012-11-07 |
MX2007011110A (en) | 2008-02-21 |
KR100911073B1 (en) | 2009-08-06 |
CN101137656B (en) | 2010-12-22 |
DE602006014516D1 (en) | 2010-07-08 |
WO2006095268A1 (en) | 2006-09-14 |
ZA200707568B (en) | 2009-09-30 |
NL300944I2 (en) | 2018-08-07 |
ATE469150T1 (en) | 2010-06-15 |
CA2600510A1 (en) | 2006-09-14 |
CA2600510C (en) | 2010-11-02 |
ES2344310T3 (en) | 2010-08-24 |
US7960407B2 (en) | 2011-06-14 |
US20090018158A1 (en) | 2009-01-15 |
CN101137656A (en) | 2008-03-05 |
PL1861400T3 (en) | 2010-09-30 |
BRPI0608819A2 (en) | 2010-01-26 |
AR055567A1 (en) | 2007-08-22 |
RU2007133802A (en) | 2009-03-20 |
KR20070103484A (en) | 2007-10-23 |
JP2006249089A (en) | 2006-09-21 |
BRPI0608819B8 (en) | 2021-05-25 |
EP1861400B1 (en) | 2010-05-26 |
TW200643021A (en) | 2006-12-16 |
EP1861400A1 (en) | 2007-12-05 |
BRPI0608819B1 (en) | 2019-11-12 |
IN2014DN09939A (en) | 2015-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0608819A8 (en) | CRYSTALLINE FORMS OF AN IMIDAZOLE DERIVATIVE | |
CY1117324T1 (en) | 1-FENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES AS PHOSPHOSTERATION INHIBITORS | |
UY31344A1 (en) | METANSULPHONAMIDS N- (3-TER-BUTIL-5- (2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1 (2H) -IL) -2-METOXI-ARIL) SUBSTITUTED, SOLVATOS, HYDRATS, CRYSTALLINE FORMS AND THEIR SALTS PHARMACEUTICALLY ACCEPTABLE, PREPARATION PROCESS, COMPOSITIONS AND APPLICATIONS. | |
MX2009000884A (en) | Pyridizinone derivatives. | |
TW200638930A (en) | Acetylene derivatives | |
CU23614B7 (en) | BETA CRYSTALINE FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
TW200833326A (en) | Chemical compounds 572 | |
MX339476B (en) | Compounds including an anti-inflammatory pharmacore and methods of use. | |
BRPI0516911A (en) | method for the preparation of an aniline compound and compound | |
NO20083491L (en) | Process for the preparation of sulfonamide-substituted alcohols and intermediates for such | |
MX2009004746A (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors. | |
MX2009004686A (en) | [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation. | |
NO20091858L (en) | Hydrobenzamide derivatives as inhibitors of HSP90 | |
ATE445593T1 (en) | ACETYLENE DERIVATIVES | |
CY1113594T1 (en) | FUMARIC SALT (ALPHA S, BETA R) -6-BROOM-ALPHA- [2- (BIMETHYLAMINE) ETHYL] -2-Methoxy-alpha-1-naphthalinyl-beta-phenyl-3-phenyl | |
BRPI0820043A8 (en) | ACTIVITIES OF THE VITAMIN D RECEPTOR AND ITS USES | |
NO20083246L (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (VRL) inhibitors | |
NO20080468L (en) | Diazepinoquinolines, their syntheses and intermediates | |
BRPI0515193A (en) | new azabicyclohexane polymorphs | |
NO20073725L (en) | CCI-779 polymorph and its use | |
NI200700175A (en) | PROCESSES FOR THE PREPARATION OF AMINOETOXIBENCIL ALCOHOLS | |
EA200901088A1 (en) | METHOD OF OBTAINING 5-BENZYLOXY-2- (4-BENZYLOXYPHENYL) -3-METHYL-1N-INDOLA | |
UY30952A1 (en) | S, S-DIOXIDE ACID POLYMORPHES 7- [3-CHLORINE-6,11-DIHYDRO-6-METHYDLIBENZO [C, F] [1,2] THIAZEPIN-11-ILAMINO] HEPTANOIC AND METHODS FOR PREPARATION AND USE | |
ECSP10010412A (en) | COMPOUND (R) -N * 6 * -ETIL-6,7-DIHIDRO-5H-INDENO (5,6-D) TIAZOL-2,6-DIAMINE AND ITS USE AS ANTIPSYCHOTIC | |
BRPI0509360A (en) | process for preparation of diazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25C | Requirement related to requested transfer of rights |
Owner name: PFIZER INC. (US) Free format text: AFIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020090065993/RJ DE 07/07/2009, E NECESSARIO COMPLEMENTAR A GUIA DE RECOLHIMENTO ATE O VALOR CORRESPONDENTE AO ATO REQUERIDO. DEVENDO INCLUSIVE RECOLHER O VALOR RELATIVO AO CUMPRIMENTO DESTA EXIGENCIA. |
|
B25A | Requested transfer of rights approved |
Owner name: RAQUALIA PHARMA INC. (JP) Free format text: TRANSFERIDO DE: PFIZER INC. |
|
B25E | Requested change of name of applicant rejected |
Owner name: RAQUALIA PHARMA INC. (JP) |
|
B25A | Requested transfer of rights approved |
Owner name: ASKAT, INC. (JP) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |